This Article Full Text Full Text (PDF) All Versions of this Article: 90/10/5551    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ciaraldi, T. P. Articles by Henry, R. R. Search for Related Content PubMed PubMed Citation Articles by Ciaraldi, T. P. Articles by Henry, R. R. Related Collections Diabetes and Insulin

Effects of the Rapid-Acting Insulin Analog Glulisine on Cultured Human Skeletal Muscle Cells: Comparisons with Insulin and Insulin-Like Growth Factor I

Veterans Affairs San Diego HealthCare System (T.P.C., L.C., V.A., S.M., R.R.H.) and Departments of Medicine (T.P.C., L.C., V.A., S.M., R.R.H.) and Pediatrics (S.A.P.), University of California-San Diego, La Jolla, California 92093

Address all correspondence and requests for reprints to: Dr. Theodore P. Ciaraldi, Department of Medicine (9111G), University of California-San Diego, La Jolla, California 92093. E-mail: tciaraldi{at}ucsd.edu.

Context: The insulin analog Lys^B3,Glu^B29-insulin (glulisine) displays accelerated in vivo bioavailability compared with native insulin.

Objective: Biological properties of this rapid-acting insulin analog were compared with the actions of native insulin and IGF-I.

Design: The effects of the hormones on hormone binding, glucose uptake, and thymidine uptake were evaluated in cultured human skeletal muscle cells.

Setting: This study was performed at a Veterans Administration hospital for patient characterization and tissue biopsies; in vitro studies were performed in a research laboratory.

Patients or Other Participants: Skeletal muscle tissue was obtained from nondiabetic (n = 13) and type 2 diabetic (n = 14) subjects.

Intervention: Cultured skeletal muscle cells were treated acutely (15–90 min) or chronically (16 h) with varying concentrations of hormones.

Main Outcome: The main study outcomes were measures of sensitivity (concentration required to attain 50% displacement of specific [¹²⁵I]insulin or [¹²⁵I]IGF-I bound and sensitivity (EC₅₀) and potency (maximal response) for hormone binding and biological responses.

Results: Insulin and glulisine were comparable in their ability to displace insulin binding. Neither insulin nor glulisine competed efficiently for IGF-I binding. Insulin, glulisine, and IGF-I were equipotent in the stimulation of glucose uptake. Maximal stimulation of phosphorylation of Akt was greatest for IGF-I, whereas sensitivities were similar to those for glucose uptake. Sensitivities were comparable in muscle cells from nondiabetic and type 2 diabetic subjects. Stimulation of [³H]thymidine uptake was most responsive to IGF-I; insulin and glulisine were equally less effective, with sensitivities approximately 1–2% of that for IGF-I. Stimulation of p42/44 MAPK phosphorylation reflected the behavior of thymidine uptake.

Conclusions: Although altered pharmacokinetics of glulisine can have therapeutic advantages, glulisine is indistinguishable from native insulin at the skeletal muscle level.